» Articles » PMID: 17278893

Simultaneous Infield Boost with Helical Tomotherapy for Patients with 1 to 3 Brain Metastases

Overview
Journal Am J Clin Oncol
Specialty Oncology
Date 2007 Feb 7
PMID 17278893
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We sought to model the feasibility of a simultaneous in field boost (SIB) to individual brain metastases during a course of whole brain radiotherapy (WBXRT) using helical tomotherapy (HT) intensity-modulated radiation therapy.

Patients And Methods: Planning computed tomography data from 14 patients with 1 to 3 brain metastases were used to model an intralesional SIB delivery that yielded a total intralesional dose of 60 Gy with a surrounding whole brain dose of 30 Gy (designed to be isoeffective to WBXRT of 30 Gy with an 18 Gy in 1 fraction radiosurgery boost). Accuracy of treatment of a phantom on the HT unit was measured. Comparisons of HT delivery versus a conventional stereotactic radiotherapy technique for a particularly challenging simulated anatomy were made.

Results: In all cases, SIB to 60 Gy with WBXRT to 30 Gy was possible while maintaining critical structures below assigned dose limits. Estimated radiation delivery time for the SIB treatment was approximately 10 minutes per fraction. Planning and treatment of the head phantom was associated with an overall accuracy of 2 mm. Comparison to conventional noncoplanar arc fractionated stereotactic radiotherapy plan demonstrated similar target coverage and improved critical tissue sparing even for a challenging anatomy with multiple lesions in the same plane as the optic apparatus.

Conclusions: Based on this study, use of an image guided SIB using HT seemed feasible and a phase I trial initiated at our institution is described. Potential advantages of this approach include frameless stereotaxis through daily megavoltage computed tomography localization, more efficient use of resources and exploitation of radiobiologic advantages of fractionation.

Citing Articles

Re-irradiation of recurrent glioblastoma using helical TomoTherapy with simultaneous integrated boost: preliminary considerations of treatment efficacy.

Arpa D, Parisi E, Ghigi G, Savini A, Colangione S, Tontini L Sci Rep. 2020; 10(1):19321.

PMID: 33168845 PMC: 7653937. DOI: 10.1038/s41598-020-75671-9.


A Phase II Multi-institutional Clinical Trial Assessing Fractionated Simultaneous In-Field Boost Radiotherapy for Brain Oligometastases.

Rodrigues G, Yartsev S, Roberge D, MacRae R, Roa W, Panet-Raymond V Cureus. 2020; 11(12):e6394.

PMID: 31942264 PMC: 6959838. DOI: 10.7759/cureus.6394.


A dosimetric comparison between CyberKnife and tomotherapy treatment plans for single brain metastasis.

Greto D, Pallotta S, Masi L, Talamonti C, Marrazzo L, Doro R Radiol Med. 2017; 122(5):392-397.

PMID: 28197874 DOI: 10.1007/s11547-017-0735-9.


Whole brain radiotherapy with adjuvant or concomitant boost in brain metastasis: dosimetric comparison between helical and volumetric IMRT technique.

Borghetti P, Pedretti S, Spiazzi L, Avitabile R, Urpis M, Foscarini F Radiat Oncol. 2016; 11:59.

PMID: 27094398 PMC: 4837558. DOI: 10.1186/s13014-016-0634-6.


Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1-3 metastases.

Bauman G, Yartsev S, Roberge D, MacRae R, Roa W, Panet-Raymond V J Neurooncol. 2016; 128(3):431-6.

PMID: 27084705 DOI: 10.1007/s11060-016-2128-7.